What does this research mean for the field?

Optimizing clinical outcomes in soft tissue sarcoma requires achieving R0 surgical margins, which is significantly enhanced by utilizing multimodal neoadjuvant therapies and performing surgeries at high-volume specialist centers. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To assess the prognostic impact of surgical margin status in soft tissue sarcoma and evaluate multimodal neoadjuvant therapies and specialized reference centers for optimizing clearance.

August 23, 2026Current Treatment Options in OncologyOpen Access

Optimising Clinical Outcomes Following R1 Resection in Soft Tissue Sarcoma: An Evidence-Based Approach

View Full Paper

Ask AI

Bookmark

To assess the prognostic impact of surgical margin status in soft tissue sarcoma and evaluate multimodal neoadjuvant therapies and specialized reference centers for optimizing clearance.
Synthesized findings from prospective trials (such as the UNRESARC phase 2 trial) and large registry cohorts, including the US National Cancer Database (N=25,406), French NETSARC, and Spanish GEIS.
Evaluated oncologic endpoints comprising R0/R1/R2 resection rates, local recurrence (LR), distant metastasis-free survival, and overall survival (OS) across surgical volumes and hospital settings.
Incomplete surgical margins significantly worsened outcomes, with 10-year local recurrence rates rising from 8% for R0 to 21% for R1 and 44% for R2 resections, conferring a nearly twofold increase in disease-specific mortality (HR 1.95).
High-volume centers (≥20 cases/year) achieved significantly lower positive margin rates than low-volume centers (12% vs. 17%, p < 0.001) and superior overall survival (HR 0.81, 95% CI 0.75–0.88), consistent with Spanish registry findings (3-year OS 82% vs. 70.4%, p = 0.003).
Preoperative hypofractionated radiotherapy combined with chemotherapy for marginally resectable tumors achieved en bloc R0 resections in 71.7% of patients, with 2-year local recurrence-free survival of 67% and distant recurrence-free survival of 57%.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Evidence review reveals that specialized center care and neoadjuvant therapy reduce positive margin rates in soft tissue sarcoma, indicating substantially improved overall survival.

Cite This Study

Remiszewski et al. (2026) studied this question.

synapsesocial.com/papers/6a8aae207677a34114446dd0 https://doi.org/10.1007/s11864-026-01410-3

View Full Paper

Ask AI

Bookmark

Implication

Evidence review reveals that specialized center care and neoadjuvant therapy reduce positive margin rates in soft tissue sarcoma, indicating substantially improved overall survival.

Optimising Clinical Outcomes Following R1 Resection in Soft Tissue Sarcoma: An Evidence-Based Approach

Key Points

Discussion

Implication

Cite This Study

Optimising Clinical Outcomes Following R1 Resection in Soft Tissue Sarcoma: An Evidence-Based Approach

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading